ITRM — Iterum Therapeutics plc

Iterum Therapeutics Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Product Revenues: $400,000 for Q3 2025, attributed to the launch of Orlynda on August 20, 2025, including initial stocking at specialty pharmacies.
• Operating Expenses: Totaled $8.1 million, up from $4.9 million in Q3 2024, driven by commercialization efforts.
  • Cost of Sales: $20,000 (primarily royalty payments).
  • R&D Expenses: $1.3 million, down from $3.1 million in Q3 2024 due to reduced CMC-related costs.
  • SG&A Expenses: $6.5 million, up from $1.8 million in Q3 2024, reflecting increased commercialization activities.
• Net Loss: $9 million (GAAP) and $7.3 million (non-GAAP), compared to $6.1 million and $4.8 million, respectively, in Q3 2024.
• Cash Position: $11 million as of September 2025, with a runway into 2026.

2. Strategic Updates and Business Highlights

• Commercial Launch of Orlynda: Initial uptake includes over 280 prescriptions from more than 100 unique prescribers, with nearly half prescribing to multiple patients.
• Payer Coverage: Currently at 16% of insured lives, with a signed rebate agreement with a top Medicare Part D pharmacy benefit manager for coverage starting in 2026 or 2027.
• Sales Force Adjustments: Reduced in-person sales representatives from 20 to 10, while augmenting efforts with virtual representatives to enhance efficiency.
• Patient Access Initiatives: Co-pay support programs are in place, and ongoing discussions with insurance carriers aim to optimize patient out-of-pocket costs.

3. Forward Guidance and Outlook

• Revenue Guidance for 2026: Expected net product revenue between $5 million and $15 million, contingent on continued sales force effectiveness and payer coverage improvements.
• Operating Expenses for 2026: Estimated between $25 million and $30 million.
• Capital Needs: Plans to raise additional capital to sustain commercialization efforts and expand into high-value territories.

4. Bad News, Challenges, or Points of Concern

• Dependence on Payer Coverage: Limited initial coverage may hinder prescription fill rates, although 40% of prescriptions have been filled through payer approval processes.
• Need for Additional Capital: The company must secure further financing to continue operations and support growth, with discussions ongoing but no viable transactions secured yet.
• Market Penetration Risks: The challenge of changing established prescribing habits in a market with ingrained practices and limited new options.

5. Notable Q&A Insights

• Metrics Reporting: Iterum plans to continue reporting detailed metrics on prescriptions and prescriber engagement in the early quarters post-launch.
• Physician Feedback: Positive initial feedback indicates that Orlynda is seen as a valuable option for treating uncomplicated urinary tract infections, particularly in high-risk patients.
• Marketing Strategies: While current focus is on field sales, there is consideration for social media and other marketing channels as capital allows.
• Interest Beyond Indication: There is inbound interest from physicians for Orlynda beyond its approved indication, which the company is monitoring while adhering to regulatory guidelines.

Overall, Iterum Therapeutics is in the early stages of commercializing Orlynda, facing both opportunities and challenges as it seeks to establish a foothold in the market.